Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

CSPC Pharmaceutical’s Megalith Subsidiary Enters $1.77 Billion siRNA Collaboration with AstraZeneca for Novel RNAi Therapeutics

Fineline Cube Jul 3, 2026
Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Fineline Cube Jul 2, 2026
Company Deals Digital

Insilico Medicine and Takeda Launch $600M Strategic AI Drug Discovery Collaboration – Pharma.AI Platform to Drive Candidate Identification for High-Potential Therapeutic Targets

Fineline Cube Jul 2, 2026
Company Deals

Nona Biosciences and Lonza Forge Strategic Alliance to Develop Best-in-Class Blood-Brain Barrier Penetration Technology for CNS Therapeutics

Fineline Cube Jul 2, 2026
Company Deals

Ipsen to Acquire Memo Therapeutics for €200M Plus Milestones, Gaining Phase II BK Virus Antibody Potravitug for Transplant Nephropathy

Fineline Cube Jul 2, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Hengrui Pharmaceuticals Secures NMPA Priority Review for Trastuzumab Rezetecan in HER2-Low Breast Cancer, Expanding Third Indication in China

Fineline Cube Jul 3, 2026
Company Drug

Edding Genor’s Trispecific Antibody GB268 Secures NMPA IND Approval for Phase Ib/II Breast Cancer Trial, Targeting TNBC and HR+/HER2- Subtypes

Fineline Cube Jul 3, 2026
Company

Gan & Lee Pharmaceuticals Reports 417 Million USD Revenue and 80.75% Profit Surge in 2024

Fineline Cube Apr 25, 2025

Gan & Lee Pharmaceuticals (SHA: 603087) reported revenues of RMB 3.045 billion (USD 417 million)...

Company Drug

Hepalink Secures SAHPRA Approval for Ivenoxin in South Africa

Fineline Cube Apr 25, 2025

Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (SHE: 002399, HKG: 9989) has announced that it has...

Company Drug

Akeso’s Penpulimab Gains FDA Approval for Nasopharyngeal Carcinoma Treatment

Fineline Cube Apr 25, 2025

China-based Akeso, Inc. (HKG: 9926) announced that it has received marketing approval from the US...

Company

Sanofi Reports Q1 Sales Growth Driven by Dupixent and New Product Launches

Fineline Cube Apr 25, 2025

French pharmaceutical giant Sanofi (NASDAQ: SNY) released its Q1 2025 financial results, reporting global net...

Company Deals

Shineco Inc. Announces Acquisition of InfiniClone for Regenerative Medicine Expansion

Fineline Cube Apr 24, 2025

US-based Shineco Inc. (NASDAQ: SISI) announced that its subsidiary Shineco Life Sciences Group Hong Kong...

Company Deals

Shenzhen Core Medical Closes Series D Round to Advance Miniaturized Artificial Hearts

Fineline Cube Apr 24, 2025

Shenzhen Core Medical Technology Co., Ltd, a developer of mechanical circulation assist systems, has reportedly...

Company Drug

Doer Biologics Begins Phase II Study of DR10624 for Steatotic Liver Disease

Fineline Cube Apr 24, 2025

China-based Zhejiang Doer Biologics Co., Ltd has announced the first patient dosing in a Phase...

Company Deals Drug

Boehringer Ingelheim Partners with Tessellate Bio on ALT Cancer Therapies

Fineline Cube Apr 24, 2025

Boehringer Ingelheim (BI), a German pharmaceutical leader, has entered into a strategic collaboration and global...

Company Deals

Genentech Collaborates with Repertoire Immune Medicines on Autoimmune Disease Therapies

Fineline Cube Apr 24, 2025

Genentech, a subsidiary of Swiss pharmaceutical leader Roche (SWX: ROG, OTCMKTS: RHHBY) , announced a collaboration...

Company Deals

AstraZeneca Expands AI Partnership with Tempus AI and Pathos AI for Oncology Research

Fineline Cube Apr 24, 2025

UK pharmaceutical leader AstraZeneca (AZ, NASDAQ: AZN) has expanded its collaboration with US-based Tempus AI,...

Company

Boston Scientific Reports 20.9% Revenue Growth in Q1 2025 Financial Results

Fineline Cube Apr 24, 2025

US medical technology giant Boston Scientific Corporation (NYSE: BSX) released its Q1 2025 financial report,...

Company Medical Device

Roche Launches Navify Chest Pain Triage Algorithm With CE Mark

Fineline Cube Apr 24, 2025

Swiss healthcare giant Roche (SWX: ROG, OTCMKTS: RHHBY) announced today that it has received CE...

Policy / Regulatory

Trump Administration Considers Tying US Drug Prices to International Benchmarks

Fineline Cube Apr 24, 2025

Reuters reported that the Trump administration is exploring a policy to tie domestic drug prices...

Company Deals Drug

Baheal Partners with Jiluntai for Commercialization of Technetium-99m-labeled Imaging Agent

Fineline Cube Apr 24, 2025

China-based health services and distribution giant Baheal Pharmaceutical Group (SHE: 301015) has entered into a...

Company

PingAn Good Doctor Reports Q1 2025 Revenue Growth and Net Profit Turnaround

Fineline Cube Apr 24, 2025

China-based Ping An Healthcare and Technology Co., Ltd (HKG: 1833), also known as PingAn Good...

Company Medical Device

MicroPort MedBot Gains NMPA Clearance for Toumai’s Remote Surgery Across Departments

Fineline Cube Apr 24, 2025

Shanghai MicroPort MedBot (Group) Co., Ltd (HKG: 2252) has announced receiving clearance from China’s National...

Company Deals

QYuns Therapeutics Signs Global Licensing Deal with Caldera for Autoimmune BsAb

Fineline Cube Apr 24, 2025

China-based Jiangsu QYuns Therapeutics Co., Ltd (HKG: 2509) has entered into a licensing agreement with...

Company

Roche Unveils $50 Billion Five-Year US Investment Plan to Expand Manufacturing and R&D

Fineline Cube Apr 23, 2025

Swiss pharmaceutical giant Roche (SWX: ROG, OTCMKTS: RHHBY) has announced a five-year investment plan totaling...

Company Deals

China Medical System Announces Spin-off of Dermavon for HKEX IPO

Fineline Cube Apr 23, 2025

China Medical System Holdings Limited (CMS; HKG: 0867) has announced the spin-off of its dermatology-focused...

Company Drug

BMS’s Cobenfy Shows Promise in Phase III ARISE Trial for Schizophrenia

Fineline Cube Apr 23, 2025

Bristol-Myers Squibb (BMS, NYSE: BMY) has announced top-line results from the Phase III ARISE trial...

Posts pagination

1 … 196 197 198 … 690

Recent updates

  • Hengrui Pharmaceuticals Secures NMPA Priority Review for Trastuzumab Rezetecan in HER2-Low Breast Cancer, Expanding Third Indication in China
  • Edding Genor’s Trispecific Antibody GB268 Secures NMPA IND Approval for Phase Ib/II Breast Cancer Trial, Targeting TNBC and HR+/HER2- Subtypes
  • Hengrui Pharmaceuticals Secures NMPA Priority Review for Trastuzumab Rezetecan in HER2-Low Breast Cancer, Expanding Third Indication in China
  • Shandong Boan Biotechnology Secures NMPA Approval for Phase II Trial of BA1106/BA1104 Combination in NSCLC, China’s First Non-IL-2-Blocking Anti-CD25 Antibody
  • CSPC Pharmaceutical’s Megalith Subsidiary Enters $1.77 Billion siRNA Collaboration with AstraZeneca for Novel RNAi Therapeutics
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui Pharmaceuticals Secures NMPA Priority Review for Trastuzumab Rezetecan in HER2-Low Breast Cancer, Expanding Third Indication in China

Company Drug

Edding Genor’s Trispecific Antibody GB268 Secures NMPA IND Approval for Phase Ib/II Breast Cancer Trial, Targeting TNBC and HR+/HER2- Subtypes

Company Drug

Hengrui Pharmaceuticals Secures NMPA Priority Review for Trastuzumab Rezetecan in HER2-Low Breast Cancer, Expanding Third Indication in China

Company Drug

Shandong Boan Biotechnology Secures NMPA Approval for Phase II Trial of BA1106/BA1104 Combination in NSCLC, China’s First Non-IL-2-Blocking Anti-CD25 Antibody

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.